Added to YB: 2026-09-18
Pitch date: 2026-09-16
CGTX [neutral]
Cognition Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Market Cap
$98.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.79
P/E
-5.35
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Biotech Conference Coverage Week 2 Day 2 part 2 - Cognition Therapeutics, Inc.
CGTX (quick overview): Cognition Therapeutics is a $1.05, high-risk CNS catalyst story with two paths to value: FDA alignment on a psychosis-focused DLB registrational trial and an NIH-funded, 545-patient early-Alzheimer’s readout expected around this time next year. Management reported 109% slowing of psychosis in SHIMMER, but incomplete FDA alignment, limited detailed SHIMMER statistics and full safety disclosure, an undefined Phase 3 timeline and cash described only through year-end 2027 remain material risks.
Read full article (2 min)